Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2022-09-28 Director's Dealing
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider trading or changes in share ownership by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2022-09-28 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Daewon Pharmaceutical, specifically detailing a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This is a regulatory filing required by the Korea Exchange (KRX) when a company decides to buy back its own shares. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports regarding share buybacks.
2022-09-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (장내매수 - open market purchases) by an executive (이소라, 전무) of Daewon Pharmaceutical. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which maps to the 'DIRS' category.
2022-09-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share transactions (purchases) made by an executive (Yoon Byung-ho) of Daewon Pharmaceutical. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider trading activity by company management.
2022-09-02 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Daewon Pharmaceutical regarding its 'Compliance Program' (CP) operations for the first half of 2022 and plans for the second half. This type of disclosure, which details internal governance, ethics, and anti-corruption management systems, does not fit into financial reporting categories like 10-K or IR. It is a standard regulatory announcement filed with the Korea Exchange (KRX) to inform stakeholders about corporate governance and compliance activities. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate governance disclosure.
2022-08-26 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Daewon Pharmaceutical Co., Ltd., covering the period from January 1, 2022, to June 30, 2022. It contains comprehensive financial statements, management discussion and analysis, and operational details, which are characteristic of an interim/quarterly report. It is not an announcement of a report, but the report itself. H1 2022
2022-08-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.